Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 12/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 5/20 | 0.36 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9944937 | 0.85 | PTGES (0.43) | PTGESCNR2CNR1CD38 | |
| SCHEMBL9944896 | 0.84 | PTGES (0.41) | PTGESALDH1A1CNR2LMNAGAA | |
| SCHEMBL9944895 | 0.80 | ALDH1A1 (0.42) | ALDH1A1CNR2LMNAMAPTKMT2A | |
| SCHEMBL14211288 | 0.77 | CNR2 (0.38) | PTGESALDH1A1CNR2CNR1 | |
| SCHEMBL9946585 | 0.76 | PTGES (0.53) | PTGESCD38 | |
| SCHEMBL9947006 | 0.76 | PTGES (0.53) | PTGESCD38 | |
| SCHEMBL9944747 | 0.75 | ALDH1A1 (0.53) | ALDH1A1MAPTHTT | |
| SCHEMBL9945003 | 0.75 | ALDH1A1 (0.53) | ALDH1A1MAPTHTT | |
| SCHEMBL9944736 | 0.75 | ALDH1A1 (0.47) | ALDH1A1CNR2CNR1 | |
| SCHEMBL9944941 | 0.75 | ALDH1A1 (0.35) | ALDH1A1CNR2CNR1CD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | PTGES 3/4885ALDH1A1 126/4885CNR2 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.